ofloxacin has been researched along with Sarcoidosis in 1 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Sarcoidosis: An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sarcoidosis is a chronic granulomatous disease for which there are limited therapeutic options." | 2.78 | Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. ( Aboud, C; Algood, H; Boyd, AS; Braun, N; Burke, VE; Drake, WP; Isom, J; Kaminski, N; King, LE; Oswald-Richter, K; Pandit, KV; Richmond, BW; Taylor, T; Yu, C, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drake, WP | 1 |
| Oswald-Richter, K | 1 |
| Richmond, BW | 1 |
| Isom, J | 1 |
| Burke, VE | 1 |
| Algood, H | 1 |
| Braun, N | 1 |
| Taylor, T | 1 |
| Pandit, KV | 1 |
| Aboud, C | 1 |
| Yu, C | 1 |
| Kaminski, N | 1 |
| Boyd, AS | 1 |
| King, LE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Study of the Effects of Antibiotics on Sarcoidosis Pathogenesis[NCT01074554] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01074554)
Timeframe: Baseline to 8 weeks
| Intervention | mm (Median) |
|---|---|
| Antibiotic Regimen | -8.4 |
| Placebo Regimen | 0.07 |
Characterization of lesion severity was conducted using Modified Sarcoidosis Activity and Severity Index (SASI), measuring erythema, induration and desquamation. The modification was that the same scale was applied to any part of the body, instead of the face alone. The scale range is 0 (no problem) to 72 (very severe). (NCT01074554)
Timeframe: Baseline to 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Antibiotic Regimen | -2.9 |
| Placebo Regimen | -0.6 |
Number of patients with a decrease in Granuloma Burden (only in those patients having granulomas present at baseline biopsy) (NCT01074554)
Timeframe: Baseline to 8 weeks
| Intervention | participants (Number) |
|---|---|
| Antibiotic Regimen | 7 |
| Placebo Regimen | 0 |
1 trial available for ofloxacin and Sarcoidosis
| Article | Year |
|---|---|
Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Azithromycin; CD4-Positive T-Lymphocytes; | 2013 |